Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.
Bone metastasis
Breast cancer
Endocrine therapy
Hormone receptor positive
Radium-223
Symptomatic skeletal event-free survival
Journal
Breast cancer research and treatment
ISSN: 1573-7217
Titre abrégé: Breast Cancer Res Treat
Pays: Netherlands
ID NLM: 8111104
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
02
05
2023
accepted:
26
09
2023
pubmed:
21
12
2023
medline:
21
12
2023
entrez:
20
12
2023
Statut:
ppublish
Résumé
Most women with advanced breast cancer have skeletal metastases. Radium-223 is an alpha-emitting radionuclide that selectively targets areas of bone metastases. Two double-blind, placebo-controlled studies of radium-223 were conducted in women with hormone receptor-positive (HR+), bone-predominant metastatic breast cancer. All patients received endocrine therapy (ET), as a single agent of the investigator's choice (Study A) or exemestane + everolimus (Study B). Patients were randomized to receive radium-223 (55 kBq/kg) or placebo intravenously every 4 weeks for six doses. Accrual was halted following unblinded interim analyses per protocol amendments, and both studies were terminated. We report pooled analyses of symptomatic skeletal event-free survival (SSE-FS; primary endpoint), radiologic progression-free survival (rPFS) and overall survival (OS; secondary), and time to bone alkaline phosphatase (ALP) progression (exploratory). In total, 382 patients were enrolled, and 196 SSE-FS events (70% planned total) were recorded. Hazard ratios (95% confidence intervals) and nominal p values for radium-223 + ET versus placebo + ET were: SSE-FS 0.809 (0.610-1.072), p = 0.1389; rPFS 0.956 (0.759-1.205), p = 0.7039; OS 0.889 (0.660-1.199), p = 0.4410; and time to bone ALP progression 0.593 (0.379-0.926), p = 0.0195. Radium-223- or placebo-related treatment-emergent adverse events were reported in 50.3% versus 35.1% of patients (grade 3/4: 25.7% vs. 8.5%), with fractures/bone-associated events in 23.5% versus 23.9%. In patients with HR+ bone-metastatic breast cancer, numeric differences favoring radium-223 + ET over placebo + ET for the primary SSE-FS endpoint were suggestive of efficacy, in line with the primary outcome measure used in the underlying phase 2 studies. No similar evidence of efficacy was observed for secondary progression or survival endpoints. Adverse events were more frequent with radium-223 + ET versus placebo + ET, but the safety profile of the combination was consistent with the safety profiles of the component drugs. Clinical trial registration numbers Study A: NCT02258464, registered October 7, 2014. Study B: NCT02258451, registered October 7, 2014.
Sections du résumé
BACKGROUND
BACKGROUND
Most women with advanced breast cancer have skeletal metastases. Radium-223 is an alpha-emitting radionuclide that selectively targets areas of bone metastases.
METHODS
METHODS
Two double-blind, placebo-controlled studies of radium-223 were conducted in women with hormone receptor-positive (HR+), bone-predominant metastatic breast cancer. All patients received endocrine therapy (ET), as a single agent of the investigator's choice (Study A) or exemestane + everolimus (Study B). Patients were randomized to receive radium-223 (55 kBq/kg) or placebo intravenously every 4 weeks for six doses. Accrual was halted following unblinded interim analyses per protocol amendments, and both studies were terminated. We report pooled analyses of symptomatic skeletal event-free survival (SSE-FS; primary endpoint), radiologic progression-free survival (rPFS) and overall survival (OS; secondary), and time to bone alkaline phosphatase (ALP) progression (exploratory).
RESULTS
RESULTS
In total, 382 patients were enrolled, and 196 SSE-FS events (70% planned total) were recorded. Hazard ratios (95% confidence intervals) and nominal p values for radium-223 + ET versus placebo + ET were: SSE-FS 0.809 (0.610-1.072), p = 0.1389; rPFS 0.956 (0.759-1.205), p = 0.7039; OS 0.889 (0.660-1.199), p = 0.4410; and time to bone ALP progression 0.593 (0.379-0.926), p = 0.0195. Radium-223- or placebo-related treatment-emergent adverse events were reported in 50.3% versus 35.1% of patients (grade 3/4: 25.7% vs. 8.5%), with fractures/bone-associated events in 23.5% versus 23.9%.
CONCLUSIONS
CONCLUSIONS
In patients with HR+ bone-metastatic breast cancer, numeric differences favoring radium-223 + ET over placebo + ET for the primary SSE-FS endpoint were suggestive of efficacy, in line with the primary outcome measure used in the underlying phase 2 studies. No similar evidence of efficacy was observed for secondary progression or survival endpoints. Adverse events were more frequent with radium-223 + ET versus placebo + ET, but the safety profile of the combination was consistent with the safety profiles of the component drugs. Clinical trial registration numbers Study A: NCT02258464, registered October 7, 2014. Study B: NCT02258451, registered October 7, 2014.
Identifiants
pubmed: 38123789
doi: 10.1007/s10549-023-07147-z
pii: 10.1007/s10549-023-07147-z
doi:
Banques de données
ClinicalTrials.gov
['NCT02258451']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
249-259Informations de copyright
© 2023. The Author(s).
Références
Coleman R, Brown J, Rathbone E, Flanagan L, Reid A, Kendall J, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I, Brown S (2020) CApecitabine plus radium-223 (Xofigo) in breast cancer patients with BONe metastases (CARBON): study protocol for a phase IB/IIA randomised controlled trial. Trials 21:89. https://doi.org/10.1186/s13063-019-3643-6
doi: 10.1186/s13063-019-3643-6
pubmed: 31941523
pmcid: 6961242
Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K (2020) Bone health in cancer: ESMO clinical practice guidelines. Ann Oncol 31:1650–1663. https://doi.org/10.1016/j.annonc.2020.07.019
doi: 10.1016/j.annonc.2020.07.019
pubmed: 32801018
Deshayes E, Roumiguie M, Thibault C, Beuzeboc P, Cachin F, Hennequin C, Huglo D, Rozet F, Kassab-Chahmi D, Rebillard X, Houede N (2017) Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther 11:2643–2651. https://doi.org/10.2147/DDDT.S122417
doi: 10.2147/DDDT.S122417
pubmed: 28919714
pmcid: 5593411
Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, Fossa SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall’Oglio M, Franzen L, Coleman R, Vogelzang NJ, O’Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland OS, Sartor O, Investigators ALSYMPCA (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223. https://doi.org/10.1056/NEJMoa1213755
doi: 10.1056/NEJMoa1213755
pubmed: 23863050
Nilsson S (2015) Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety. Expert Opin Drug Saf 14:1127–1136. https://doi.org/10.1517/14740338.2015.1045874
doi: 10.1517/14740338.2015.1045874
pubmed: 26022669
Nilsson S, Cislo P, Sartor O, Vogelzang NJ, Coleman RE, O’Sullivan JM, Reuning-Scherer J, Shan M, Zhan L, Parker C (2016) Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study. Ann Oncol 27:868–874. https://doi.org/10.1093/annonc/mdw065
doi: 10.1093/annonc/mdw065
pubmed: 26912557
pmcid: 4843190
Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA (2020) Phase II study of radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med 9:1025–1032. https://doi.org/10.1002/cam4.2780
doi: 10.1002/cam4.2780
pubmed: 31849202
Dizdarevic S, McCready R, Vinjamuri S (2020) Radium-223 dichloride in prostate cancer: proof of principle for the use of targeted alpha treatment in clinical practice. Eur J Nucl Med Mol Imaging 47:192–217. https://doi.org/10.1007/s00259-019-04475-5
doi: 10.1007/s00259-019-04475-5
pubmed: 31471713
Takalkar A, Paryani B, Adams S, Subbiah V (2015) Radium-223 dichloride therapy in breast cancer with osseous metastases. BMJ Case Rep. https://doi.org/10.1136/bcr-2015-211152
doi: 10.1136/bcr-2015-211152
pubmed: 26581701
pmcid: 4654149
Coleman R, Aksnes AK, Naume B, Garcia C, Jerusalem G, Piccart M, Vobecky N, Thuresson M, Flamen P (2014) A phase IIa, nonrandomized study of radium-223 dichloride in advanced breast cancer patients with bone-dominant disease. Breast Cancer Res Treat 145:411–418. https://doi.org/10.1007/s10549-014-2939-1
doi: 10.1007/s10549-014-2939-1
pubmed: 24728613
pmcid: 4025174
Costa RP, Tripoli V, Princiotta A, Murabito A, Licari M, Piazza D, Verderame F, Pinto A (2019) Therapeutic effect of RA223 in the management of breast cancer bone metastases. Clin Ter 170:e1–e3. https://doi.org/10.7417/CT.2019.2100
doi: 10.7417/CT.2019.2100
pubmed: 30789190
Coleman R (2016) Treatment of metastatic bone disease and the emerging role of radium-223. Semin Nucl Med 46:99–104. https://doi.org/10.1053/j.semnuclmed.2015.10.012
doi: 10.1053/j.semnuclmed.2015.10.012
pubmed: 26897713
Coleman RE, Fried G, Kim S-B, Kuchuk I, Kiesl D, Ramos M, Sohn J, Siegel J, Li R, Uema D, Wagner V, Rugo HS (2021) Radium-223 in women with HR-positive bone-metastatic breast cancer receiving endocrine therapy: international phase 2, randomized, double-blind, placebo-controlled trial. Cancer Res. https://doi.org/10.1158/1538-7445.Sabcs20-ps14-01
doi: 10.1158/1538-7445.Sabcs20-ps14-01
Rugo HS, Drumea K, Lee SC, Campone M, Van Poznak C, Neven P, Vega Alonso E, Naume B, Siegel JM, Li R, Uema D, Wagner VJ, Coleman RE (2022) Radium-223 (223Ra) in combination with exemestane and everolimus (EXE-EVE) in patients (pts) with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2−) metastatic breast cancer (MBC) with bone metastases: a phase 2 study. Ann Oncol 33(Suppl 3):182P. https://doi.org/10.1016/annonc/annonc894
doi: 10.1016/annonc/annonc894
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, Barrios CH, Bergh J, Bhattacharyya GS, Biganzoli L, Boyle F, Cardoso MJ, Carey LA, Cortés J, El Saghir NS, Elzayat M, Eniu A, Fallowfield L, Francis PA, Gelmon K, Gligorov J, Haidinger R, Harbeck N, Hu X, Kaufman B, Kaur R, Kiely BE, Kim SB, Lin NU, Mertz SA, Neciosup S, Offersen BV, Ohno S, Pagani O, Prat A, Penault-Llorca F, Rugo HS, Sledge GW, Thomssen C, Vorobiof DA, Wiseman T, Xu B, Norton L, Costa A, Winer EP (2020) 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 31:1623–1649. https://doi.org/10.1016/j.annonc.2020.09.010
doi: 10.1016/j.annonc.2020.09.010
pubmed: 32979513
Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS (2021) Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol 39:3959–3977. https://doi.org/10.1200/jco.21.01392
doi: 10.1200/jco.21.01392
pubmed: 34324367
pmcid: 8659999
Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J, Taylor C, Eastell R, Murden G, Brown SR, Rathbone E, Brown J (2022) A phase IB and randomised phase IIA trial of CApecitabine plus radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. J Bone Oncol 35:100442. https://doi.org/10.1016/j.jbo.2022.100442
doi: 10.1016/j.jbo.2022.100442
pubmed: 35800293
pmcid: 9253642
Houssiau H, Duhoux FP, François D, Seront E (2022) Radium-223 as an additional therapeutic strategy in highly selected patients with metastatic breast cancer: a case report. Front Oncol 12:896301. https://doi.org/10.3389/fonc.2022.896301
doi: 10.3389/fonc.2022.896301
pubmed: 35712506
pmcid: 9195502
Wang R, Zhu Y, Liu X, Liao X, He J, Niu L (2019) The clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 19:1091. https://doi.org/10.1186/s12885-019-6311-z
doi: 10.1186/s12885-019-6311-z
pubmed: 31718602
pmcid: 6852913